Results 31 to 40 of about 9,994 (168)
Medicinal Research Reviews, EarlyView.ABSTRACT Natural products (NPs) have historically yielded numerous therapeutic agents, yet their integration into modern drug discovery has been constrained by chemical complexity, low abundance, laborious dereplication, and limited target annotation.
Antonio Lavecchia
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson +13 more
wiley +1 more source
Journal of Neuroinflammation, 2018 Background Neuroinflammation plays an important role in the onset and progression of neurodegenerative diseases such as Alzheimer’s disease. Lipopolysaccharide (LPS, endotoxin) levels are higher in the brains of Alzheimer’s disease patients and are ...
Yi Liu +9 more
doaj +1 more source
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Brain Sciences, 2021 Alzheimer’s disease (AD) is a burgeoning social and healthcare problem. Cholinesterase inhibitors (ChEIs) are employed for symptomatic treatment of AD, but often elicit adverse drug reactions (ADRs).
Hafsa Amat-ur-Rasool +3 more
doaj +1 more source
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
Clinical Interventions in Aging, 2009 Ben SeltzerGeriatric Research, Education and Clinical Center, VA Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USAAbstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine ...
Ben Seltzer
doaj
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Dreaming, a common yet mysterious cognitive phenomenon, is an involuntary process experienced by individuals during sleep. Although the fascination with dreams dates back to ancient times and gained therapeutic significance through psychoanalysis in the early twentieth century, its scientific investigation only gained momentum with the ...
Carlotta Mutti +2 more
wiley +1 more source
Psychiatry and Clinical Neurosciences, EarlyView.Aim To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated
Aran Tajika +5 more
wiley +1 more source
Food Frontiers, Volume 7, Issue 5, September 2026.Ketogenic diet (KD) confers neuroprotection in Alzheimer's disease by inhibiting microglial HDAC3. This simultaneously enhances Aβ clearance via TREM2‐mediated phagocytosis and AMPK–ULK1‐driven autophagy, while suppressing NLRP3 inflammasome activation, ultimately attenuating Aβ/tau pathology and neuronal damage. ABSTRACT Growing evidence suggests that
Mingxiao Zheng +7 more
wiley +1 more source
Frontiers in Pharmacology, 2021 Patient’s poor compliance and the high risk of toxic effects limit the clinical use of galantamine hydrobromide. To overcome these drawbacks, the sustained-release galantamine pamoate microspheres (GLT-PM-MS) were successfully developed using an oil ...
Liping Du +8 more
doaj +1 more source